CitiusTech ties up with Tata Memorial Hospital for paediatric cancer care

Our Bureau Mumbai | Updated on January 12, 2018

CitiusTech has entered into an agreement with Tata Memorial Hospital and extended its support for the use of Percutaneous Intravenous Central Catheters (PICC lines) amongst children suffering from cancer. This will eliminate the need of frequent needle pricks, saving the children from psychological trauma associated with cancer treatment.

CitiusTech, a provider of technology services and solutions, will also offer technology consulting to build a robust hospital information system for the hospital. These are part of its Corporate Social Responsibility (CSR) initiatives, the company said in a statement.

CitiusTech has provided financial aid to Tata Memorial Hospital over the past couple of years for the use of PICC lines and over 200 children have benefited from this programme till date. The PICC lines can also be used for providing medications and concentrated intravenous nutrition fluid to the child, making the treatment more comfortable and supporting faster recovery of these children.

“In addition to providing financial support, we look forward to sharing our learning in healthcare technology to help Tata Memorial Hospital build a globally-recognized healthcare technology platform,” said Jagdish Moorjani, COO at CitiusTech.

“Central venous lines (PICC) are an essential part of making chemotherapy treatment possible and effective. The PICC lines avoid multiple needle pricks and make the journey of childhood cancer more acceptable. CitiusTech has gracefully adopted this project for three years where they would be providing the central lines and supporting the care of these devices for 360 children each year. Tata Memorial Hospital is grateful to CitiusTech for this partnership,” said Anil D’Cruz, Director at Tata Memorial Hospital.

Published on January 31, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like